...
首页> 外文期刊>Virchows Archiv >Guideline on the requirements of external quality assessment programs in molecular pathology
【24h】

Guideline on the requirements of external quality assessment programs in molecular pathology

机译:分子病理学中外部质量评估计划要求的指南

获取原文
获取原文并翻译 | 示例
           

摘要

Molecular pathology is an integral part of daily diagnostic pathology and used for classification of tumors, for prediction of prognosis and response to therapy, and to support treatment decisions. For these reasons, analyses in molecular pathology must be highly reliable and hence external quality assessment (EQA) programs are called for. Several EQA programs exist to which laboratories can subscribe, but they vary in scope, number of subscribers, and execution. The guideline presented in this paper has been developed with the purpose to harmonize EQA in molecular pathology. It presents recommendations on how an EQA program should be organized, provides criteria for a reference laboratory, proposes requirements for EQA test samples, and defines the number of samples needed for an EQA program. Furthermore, a system for scoring of the results is proposed as well as measures to be taken for poorly performing laboratories. Proposals are made regarding the content requirements of an EQA report and how its results should be communicated. Finally, the need for an EQA database and a participant manual are elaborated. It is the intention of this guideline to improve EQA for molecular pathology in order to provide more reliable molecular analyses as well as optimal information regarding patient selection for treatment.
机译:分子病理学是日常诊断病理学不可或缺的一部分,可用于肿瘤分类,预测预后和对治疗的反应以及支持治疗决策。由于这些原因,分子病理学分析必须高度可靠,因此需要进行外部质量评估(EQA)程序。实验室可以订阅几个EQA程序,但是它们的范围,订阅者数量和执行方式各不相同。本文提出的指南是为了协调分子病理学中的EQA而制定的。它提出了有关如何组织EQA计划的建议,为参考实验室提供了标准,提出了对EQA测试样本的要求,并定义了EQA计划所需的样本数量。此外,提出了一种对结果进行评分的系统,以及针对表现不佳的实验室应采取的措施。提出了有关EQA报告的内容要求以及应如何传达其结果的建议。最后,阐述了对EQA数据库和参与者手册的需求。该指南旨在改善分子病理学的EQA,以便提供更可靠的分子分析以及有关患者选择治疗的最佳信息。

著录项

  • 来源
    《Virchows Archiv》 |2013年第1期|27-37|共11页
  • 作者单位

    Department of Pathology 824 Radboud University Nijmegen Medical Centre">(1);

    Cell Biology and Biotherapy Unit INT-Fondazione Pascale">(2);

    Manchester University and Christie Hospital NHS Foundation Trust">(3);

    Laboratory for Molecular Diagnostics H. Hartziekenhuis Roeselare-Menen">(4);

    Dipartimento di Anatomia Patologica e Citopatologia IRCCS Istituto Nazionale Tumori Fondazione G. Pascale">(5);

    Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Medical Faculty/ Centro Hospitalar de São João">(6);

    Merck Serono Global Research Early Development—Oncology Platform Merck KGaA">(7);

    Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara Seconda Università di Napoli">(8);

    Warwick Medical School Clinical Sciences Building University Hospitals Coventry and Warwickshire">(9);

    UK NEQAS for Molecular Genetics UK NEQAS The Royal Infirmary of Edinburgh">(10);

    Clinical Molecular Pathology Unit Clinical Pathology and Cytology Sahlgrenska University Hospital and Sahlgrenska Cancer Center the Sahlgrenska Academy University of Gothenburg">(11);

    Department of Pathology 824 Radboud University Nijmegen Medical Centre">(1);

    European Molecular Genetics Quality Network (EMQN) Genetic Medicine St. Mary’s Hospital">(12);

    Institute of Pathology Hannover Medical School">(13);

    Department of Pathology 824 Radboud University Nijmegen Medical Centre">(1);

    Department of Human Genetics Radboud University Nijmegen Medical Centre">(14);

    Center of Predictive Molecular Medicine University-Foundation">(15);

    BioMarker Solutions Ltd. London UK GeneKor A.E.">(16);

    Molecular Diagnostics;

    Quality Control Business Life Technologies Europe BV">(17);

    Medical Sciences Amgen Inc.">(18);

    European Molecular Genetics Quality Network (EMQN) Genetic Medicine St. Mary’s Hospital">(19);

    Medical Oncology S.Orsola-Malpighi Hospital">(20);

    Institut Curie">(21);

    Department of Pathology and Medical Biology University Hospital Groningen and University of Groningen">(22);

    Department of Public Health Biomedical Quality Assurance Research Unit University of Leuven">(23);

    Medical Oncology Service Catalan Institute of Oncology Hospital Germans TriasiPujol">(24);

    Pangaea Biotech-Dexeus Institute">(29);

    Department of Oncology Laboratory of Molecular Digestive Oncology University of Leuven">(25);

    Department of Pathology and Medical Biology University of Groningen and University Medical Center Groningen">(26);

    Pathology VU University Medical Center">(27);

    Department of Epidemiology and Biostatistics VU University Medical Center">(28);

    Department of Pathology 824 Radboud University Nijmegen Medical Centre">(1);

    Department of Public Health Biomedical Quality Assurance Research Unit University of Leuven">(23);

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Molecular pathology; External quality assessment; Oncology; Guideline;

    机译:分子病理学;外部质量评估;肿瘤学指导方针;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号